A Quick Peek into the FutureGlaucoma Therapeutic Innovations
Ike K Ahmed MD GoEyeCare Trillium Health Partners University of Toronto
1
IK Ahmed MD
DisclosuresAdeTherapeutics: C Accelerated Vision: C ACE Vision Group: C Alcon: C, R AMO: C, R, S Aerie: C Allergan: C, R Aquesys: C, R Bausch & Lomb: C Carl Zeiss: C, R, S Clarity Medical Systems: C Croma Pharma: C Envisia Therapeutics: C Eyelight: C ForSight Labs: C
Glaukos: C, R, S InnFocus: C Iridex: C, R Ivantis: C, R, S LayerBio: C New World Medical: R Omega Ophthalmics: C ONO Pharma: C PolyActiva: C Sanoculis: C Science Based Health: C SOLX: C, R Stroma: C Transcend: C, R TrueVision: C
C = Consultant R = Research Support
S = Speakers Honorarium
2
IK Ahmed MD
Therapeutics Drug Delivery
MIGS
Neuroprotection Regeneration
Diagnostics Early Detection
Progression IOP Telemetry
I n n o v a t i o n S p a n
3
IkeKAhmedMD
OcularSurface
SustainedReleaseApproaches
Intravitreal
Suprachoroidal
SubconjunctivalScleral
AnteriorChamber
4
IkeKAhmedMD
Latanoprost-ElutingContactLens
• Toaddresspoorcompliance
• PreservativeFree
• Canbemadewithrefractive
errorcorrection
• Sustained,controlleddelivery
• Therapeuticpayload
• Durationof2weeksor1month
• Couldbeusedasacontinuous
wearlensDr.JosephB.Ciolino,Dr.DanielS.Kohane
MassachusettsEyeandEarInfirmary,MIT,BostonChildren’sHospital
5
IkeKAhmedMD
Drug-ElutingPunctalPlugSystem MatiTherapeutics
6
Drug-ElutingPunctalPlugs&InjectableDepots
• Drug-elutingpunctumplugs
– Biodegradablemicrospheresinhydrogel– Travoprostdrugrelease=2-3months– Comfortandretentionupto3months
• ReSure®Sealant
– Insituforminghydrogelbarrier– Localizedincisionprotectionfromfluidegress– Preparedandappliedinlessthan30seconds
• Drug-elutinginjectabledepots
– 4-6monthssustainedrelease–anti-VEGF*– Intraocularbiocompatibilityandlocalization– 30gaugeneedleintravitrealinjectability
OcularTherapeutix
7
IK Ahmed MD
Forsight Vision5 Helios Insert
• Fornix ocular insert
• Bimatoprost elution
8
Collagen added to NaCl
<1 minute after
InsituPolymerizableCollagenSolutionEuclidSystemsCorp
• Injectableviscousformssolidgel
drugdepotwhenexposedto
physiologicalfluidsorinjectedinto
tissueswithin60seconds
• SubconjunctivaIinjection
• Latanoprostgel=>1month
9
IkeKAhmedMD
ImplantableCollagenFilms/WafersEuclidSystemsCorp
• Biodegradablefilmcanbe
preparedtodegradefrom
minutesto>6months
• Subconjunctivalinjection
• Latanoprostcollagenwafer
showedsustainedreleasefor
180dayswithminimalburst
10
Day 1
Day 7
Day 14
Bioerodibleimplantvisibly
decreasinginsizeover
time
Nosignofadverse
responsetoimplant
Photographsofarabbiteyeupto14days
Drug-PolymerConjugateImplant PolyActivia
Subconjuntivalor
intravitreal21Ginjection
Combinationdrugs
3-6mosduration
11
PRINTDexamethasonePLGAimplants:
2.24μg/implant(17.5%w/w)
Implants• Extendedreleaseformulationsofbiologics
andsmallmoleculedrugs
• Reproducibleimplantsize,shape,
compositionanddose
• Simpledelivery
Micro/NanoParticles• Topicaldeliverywithfewerdoses
• Sustainedrelease
• Permeationandtargetedtoincreaseefficacy
LowmodulusPRINTmonodisperse
microparticles
“PRINT”EngineeredNanoparticlesEnvisiaTherapeutics
12
IkeKAhmedMD
Intracameral(Day12)PRINTFormulation#7
Subconjuctival(Day12)PRINTFormulation#7
Intracameralinjections(1implant/eye)Formulation#7:250μmx250μmx1,500μm
drugimplant
Subconjuctivalinjections(1implant/eye)Formulation#7:250μmx250μmx1,500μm
drugimplant.
Preliminarystudiesdemonstratesuccessfulintravitreal,intracameralandsubconjuctivalinjectionswithPRINTimplantsinrabbitsNopost-insertionadverseeffectsobserved
“PRINT”EngineeredNanoparticlesEnvisiaTherapeutics
13
AllerganBimatoprostSRIntracameralBioerodibleDrugPellet
Abioerodible,extended-releasedrugpelletthatcanbeadministeredviainjectionwithasmallgaugeneedle-injectortothefrontoftheeye
14
ReplenishOphthalmicMicroPump
• Subconjunctivalimplant
• Injectprogrammedamountof
drugatsettimes
• MEMSdevice
• 12monthdrugsupply
• Refilledwith31Gneedle
• Rechargewirelessly
15
IK Ahmed MD
Intravitreal Encapsulated Cell Therapy
2015-04-25, 1:22 AMEncapsulated Cell Technology-ECT | Nuerotech Pharmaceuticals
Page 1 of 2http://www.neurotechusa.com/ect-platform.html
Watch ECT Principles Video
Watch ECT Design Video
Watch ECT Implantation Video
ECT PlatformNeurotech’s patented core technology platform, Encapsulated Cell Therapy (ECT), is a first-in-class, versatiledrug delivery platform in development for the treatment of a broad array of eye diseases. ECT is a geneticallyengineered ocular implant that enables continuous production of therapeutic proteins to the eye for over 2years. Additionally, the therapy is reversible by simply removing the implant.
The ECT implant is inserted into the vitreous through a single incision and sutured in place in a 20-minuteoutpatient surgical procedure. Watch Video.
ECT implants been successfully implanted in over 400 subjects for up to 5 years duration.
Customized Therapeutic Cell Line
The basis of the ECT platform is the customized NTC-200 cell line, a proprietary cell line derived from normalhuman retinal pigment epithelial cells. NTC-200 cells were initially screened from many other cell types asbeing remarkably hardy: the cells thrive under low oxygen and low nutrient conditions, while being amenable togenetic manipulations under stringent selection methods. Recombinant cell lines derived from transfectedNTC-200 cells are able to secrete major classes of therapeutics, including antibodies, fusion proteins, andgrowth factors. Cell lines are isolated from the host inside a sealed polymer device.
Versatile Platform
The ECT device is fabricated from medical-grade plastics and consists of a semi-permeable exterior capsuleand internal scaffolding, which allows for controlled cell growth and continuous protein production within thecartridge. Watch Video
The semi-permeability of the ECT capsule allows oxygen and nutrients in the vitreous to freely diffuse inward,and allows therapeutic to freely diffuse outward. Different device geometries and nutrient conditioning areexplored for each clinical cell line produced, and the configuration best addressing the target disease aretested in models for bio-compatibility. Watch Video
The versatility of the ECT device enables long-term and continuous targeted delivery of single and combinationtherapeutics, both internally developed at Neurotech, as well as those developed by potential partners forfuture collaboration.
Dedicated Manufacturing
Neurotech’s dedicated, in-house manufacturing operations, located at their corporate headquarters inCumberland, RI, are held within a 26,000 square foot facility and operate under GMP guidelines. The ECTmanufacturing facility is designed for clinical development and commercial launch, with the capacity ofproducing at least 150,000 ECT units a year. Cells are inserted into ECT devices in a controlled environmentby proprietary semi-automated liquid injectors and performed under cGMP clean room environments. Finishedimplants are held in nutrient media containers and monitored under strict cGMP quality guidelines. ECTimplants are then shipped to trained ophthalmic surgeons for implantation into patients.
Privacy Policy © 2014-2015 Neurotech
NEWS UPDATE
Find out about the latest news at Neurotech.
Home | About Neurotech | Platform & Pipeline | Newsroom | Contact
ECT Platform ECT Pipeline NT-503 ECT NT-506 ECT NT-501 ECT
About Neurotech Platform & Pipeline Newsroom Contact
2015-04-25, 1:22 AMEncapsulated Cell Technology-ECT | Nuerotech Pharmaceuticals
Page 1 of 2http://www.neurotechusa.com/ect-platform.html
Watch ECT Principles Video
Watch ECT Design Video
Watch ECT Implantation Video
ECT PlatformNeurotech’s patented core technology platform, Encapsulated Cell Therapy (ECT), is a first-in-class, versatiledrug delivery platform in development for the treatment of a broad array of eye diseases. ECT is a geneticallyengineered ocular implant that enables continuous production of therapeutic proteins to the eye for over 2years. Additionally, the therapy is reversible by simply removing the implant.
The ECT implant is inserted into the vitreous through a single incision and sutured in place in a 20-minuteoutpatient surgical procedure. Watch Video.
ECT implants been successfully implanted in over 400 subjects for up to 5 years duration.
Customized Therapeutic Cell Line
The basis of the ECT platform is the customized NTC-200 cell line, a proprietary cell line derived from normalhuman retinal pigment epithelial cells. NTC-200 cells were initially screened from many other cell types asbeing remarkably hardy: the cells thrive under low oxygen and low nutrient conditions, while being amenable togenetic manipulations under stringent selection methods. Recombinant cell lines derived from transfectedNTC-200 cells are able to secrete major classes of therapeutics, including antibodies, fusion proteins, andgrowth factors. Cell lines are isolated from the host inside a sealed polymer device.
Versatile Platform
The ECT device is fabricated from medical-grade plastics and consists of a semi-permeable exterior capsuleand internal scaffolding, which allows for controlled cell growth and continuous protein production within thecartridge. Watch Video
The semi-permeability of the ECT capsule allows oxygen and nutrients in the vitreous to freely diffuse inward,and allows therapeutic to freely diffuse outward. Different device geometries and nutrient conditioning areexplored for each clinical cell line produced, and the configuration best addressing the target disease aretested in models for bio-compatibility. Watch Video
The versatility of the ECT device enables long-term and continuous targeted delivery of single and combinationtherapeutics, both internally developed at Neurotech, as well as those developed by potential partners forfuture collaboration.
Dedicated Manufacturing
Neurotech’s dedicated, in-house manufacturing operations, located at their corporate headquarters inCumberland, RI, are held within a 26,000 square foot facility and operate under GMP guidelines. The ECTmanufacturing facility is designed for clinical development and commercial launch, with the capacity ofproducing at least 150,000 ECT units a year. Cells are inserted into ECT devices in a controlled environmentby proprietary semi-automated liquid injectors and performed under cGMP clean room environments. Finishedimplants are held in nutrient media containers and monitored under strict cGMP quality guidelines. ECTimplants are then shipped to trained ophthalmic surgeons for implantation into patients.
Privacy Policy © 2014-2015 Neurotech
NEWS UPDATE
Find out about the latest news at Neurotech.
Home | About Neurotech | Platform & Pipeline | Newsroom | Contact
ECT Platform ECT Pipeline NT-503 ECT NT-506 ECT NT-501 ECT
About Neurotech Platform & Pipeline Newsroom Contact
2015-04-25, 1:22 AMEncapsulated Cell Technology-ECT | Nuerotech Pharmaceuticals
Page 1 of 2http://www.neurotechusa.com/ect-platform.html
Watch ECT Principles Video
Watch ECT Design Video
Watch ECT Implantation Video
ECT PlatformNeurotech’s patented core technology platform, Encapsulated Cell Therapy (ECT), is a first-in-class, versatiledrug delivery platform in development for the treatment of a broad array of eye diseases. ECT is a geneticallyengineered ocular implant that enables continuous production of therapeutic proteins to the eye for over 2years. Additionally, the therapy is reversible by simply removing the implant.
The ECT implant is inserted into the vitreous through a single incision and sutured in place in a 20-minuteoutpatient surgical procedure. Watch Video.
ECT implants been successfully implanted in over 400 subjects for up to 5 years duration.
Customized Therapeutic Cell Line
The basis of the ECT platform is the customized NTC-200 cell line, a proprietary cell line derived from normalhuman retinal pigment epithelial cells. NTC-200 cells were initially screened from many other cell types asbeing remarkably hardy: the cells thrive under low oxygen and low nutrient conditions, while being amenable togenetic manipulations under stringent selection methods. Recombinant cell lines derived from transfectedNTC-200 cells are able to secrete major classes of therapeutics, including antibodies, fusion proteins, andgrowth factors. Cell lines are isolated from the host inside a sealed polymer device.
Versatile Platform
The ECT device is fabricated from medical-grade plastics and consists of a semi-permeable exterior capsuleand internal scaffolding, which allows for controlled cell growth and continuous protein production within thecartridge. Watch Video
The semi-permeability of the ECT capsule allows oxygen and nutrients in the vitreous to freely diffuse inward,and allows therapeutic to freely diffuse outward. Different device geometries and nutrient conditioning areexplored for each clinical cell line produced, and the configuration best addressing the target disease aretested in models for bio-compatibility. Watch Video
The versatility of the ECT device enables long-term and continuous targeted delivery of single and combinationtherapeutics, both internally developed at Neurotech, as well as those developed by potential partners forfuture collaboration.
Dedicated Manufacturing
Neurotech’s dedicated, in-house manufacturing operations, located at their corporate headquarters inCumberland, RI, are held within a 26,000 square foot facility and operate under GMP guidelines. The ECTmanufacturing facility is designed for clinical development and commercial launch, with the capacity ofproducing at least 150,000 ECT units a year. Cells are inserted into ECT devices in a controlled environmentby proprietary semi-automated liquid injectors and performed under cGMP clean room environments. Finishedimplants are held in nutrient media containers and monitored under strict cGMP quality guidelines. ECTimplants are then shipped to trained ophthalmic surgeons for implantation into patients.
Privacy Policy © 2014-2015 Neurotech
NEWS UPDATE
Find out about the latest news at Neurotech.
Home | About Neurotech | Platform & Pipeline | Newsroom | Contact
ECT Platform ECT Pipeline NT-503 ECT NT-506 ECT NT-501 ECT
About Neurotech Platform & Pipeline Newsroom Contact
16
IK Ahmed MD
Microinvasive Glaucoma Surgery• Ab-interno approach
• Minimally traumatic
• At least modest efficacy
• Extremely high safety profile
• Rapid recovery
17
IK Ahmed MD
iStent iStent inject Hydrus
Cypass iStent supra Xen
18
IK Ahmed MD
Suprachoroidal Micro-StentTranscend CyPass Micro-Stent
Investigational device. Not approved by the FDA.
19
IK Ahmed MD
20
IK Ahmed MD
21
IK Ahmed MD
AqueSys XEN Implant Generations
Investigational device. Not approved by the FDA.
22
IK Ahmed MD
23
IK Ahmed MD
24
IK Ahmed MDIOP 12
25
IK Ahmed MD
Glaucoma Treatment Algorithm
1 Med Multiple Meds SLT Multiple
Meds Trab 2nd Trab or Tube
1 Med SLT
Drug Delivery MIGS MIGS2 Trab
or Tube
Phaco + MIGS
Now & Potentially in 5 years
Level of Invasiveness
26